CTOs on the Move

Antiva Biosciences

www.antivabio.com

 
Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva`s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.antivabio.com
  • 6000 Shoreline Court Suite 203
    South San Francisco, CA USA 94080
  • Phone: 650.822.1400

Executives

Name Title Contact Details

Funding

Antiva Biosciences raised $22M on 03/28/2017
Antiva Biosciences raised $60M on 07/10/2018
Antiva Biosciences raised $31M on 11/02/2021

Similar Companies

Inozyme

We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.

Nashai

Nashai is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Allon Therapeutics

Allon Therapeutics, Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.